These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

739 related items for PubMed ID: 31129129

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A.
    N Engl J Med; 2021 Jul 08; 385(2):142-152. PubMed ID: 33891380
    [Abstract] [Full Text] [Related]

  • 9. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H, ERASURE Study Japanese subgroup.
    J Dermatol; 2014 Dec 08; 41(12):1039-46. PubMed ID: 25354738
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. IL-17 Blockade in Psoriasis.
    Burkett PR, Kuchroo VK.
    Cell; 2016 Dec 15; 167(7):1669. PubMed ID: 27984714
    [Abstract] [Full Text] [Related]

  • 12. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, Papavassilis C, Mpofu S.
    J Drugs Dermatol; 2015 Aug 15; 14(8):821-33. PubMed ID: 26267726
    [Abstract] [Full Text] [Related]

  • 13. Anti IL-17 in psoriasis.
    Ly K, Smith MP, Thibodeaux Q, Reddy V, Liao W, Bhutani T.
    Expert Rev Clin Immunol; 2019 Nov 15; 15(11):1185-1194. PubMed ID: 31603358
    [Abstract] [Full Text] [Related]

  • 14. A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis.
    Liu Y, Zhang C, Li B, Yu C, Bai X, Xiao C, Wang L, Dang E, Yang L, Wang G.
    J Dermatol Sci; 2021 Feb 15; 101(2):84-92. PubMed ID: 33334656
    [Abstract] [Full Text] [Related]

  • 15. IL-17 for therapy.
    Kurschus FC, Moos S.
    J Dermatol Sci; 2017 Sep 15; 87(3):221-227. PubMed ID: 28633806
    [Abstract] [Full Text] [Related]

  • 16. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
    van Vugt LJ, van den Reek JMPA, Meulewaeter E, Hakobjan M, Heddes N, Traks T, Kingo K, Galluzzo M, Talamonti M, Lambert J, Coenen MJH, de Jong EMGJ.
    J Eur Acad Dermatol Venereol; 2020 Jan 15; 34(1):112-118. PubMed ID: 31287604
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. IκBζ is a key player in the antipsoriatic effects of secukinumab.
    Bertelsen T, Ljungberg C, Litman T, Huppertz C, Hennze R, Rønholt K, Iversen L, Johansen C.
    J Allergy Clin Immunol; 2020 Jan 15; 145(1):379-390. PubMed ID: 31622687
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.